Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 18/20 | 0.66 |
| ▸ | HRH1 | P35367 | 1/20 | 0.66 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16697458 | 1.00 | LPAR1 (0.66) | LPAR1HRH1LPAR3GAASMN1; SMN2 | |
| SCHEMBL16697565 | 0.92 | LPAR1 (0.57) | LPAR1HRH1LPAR3GAASMN1; SMN2 | |
| SCHEMBL16697563 | 0.92 | LPAR1 (0.57) | LPAR1HRH1LPAR3GAASMN1; SMN2 | |
| SCHEMBL16698307 | 0.91 | LPAR1 (0.68) | LPAR1HRH1LPAR3GAASMN1; SMN2 | |
| SCHEMBL16698308 | 0.91 | LPAR1 (0.68) | LPAR1HRH1LPAR3GAASMN1; SMN2 | |
| SCHEMBL14710482 | 0.91 | LPAR1 (0.70) | LPAR1HRH1LPAR3 | |
| SCHEMBL16697998 | 0.91 | LPAR1 (0.70) | LPAR1HRH1LPAR3 | |
| SCHEMBL16707815 | 0.88 | LPAR1 (0.79) | LPAR1HRH1LPAR3 | |
| SCHEMBL16697742 | 0.85 | LPAR1 (0.65) | LPAR1HRH1LPAR3GAASMN1; SMN2 | |
| SCHEMBL16697740 | 0.85 | LPAR1 (0.65) | LPAR1HRH1LPAR3GAASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150133512-A1 | N-ARYLTRIAZOLE COMPOUNDS AS LPAR ANTAGONISTS | HOFFMANN-LA ROCHE INC. | 2015-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150133512-A1 | N-ARYLTRIAZOLE COMPOUNDS AS LPAR ANTAGONISTS | LPAR1, LPAR2, LPAR3 | LPAR1 1/4885HRH1 819/4885LPAR3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.